

**Changes to the CalOptima Medi-Cal Physician Administered Drugs, OneCare Formulary and OneCare Connect Formulary  
Pharmacy & Therapeutics Committee Meeting – May 19, 2022**

Effective Dates	Brand Name†	Generic Name	Drug Class	Strength	Dosage Form	Committee Action for CalOptima Medi-Cal Physician Administered Drugs	Committee Action for OneCare/OneCare Connect
7/1/22	Trudhesa	Dihydroergotamine mesylate	Antimigraine Agent	0.725 mg/actuation	Aerosol solution	N/A	Non-Formulary
7/1/22	Qulipta	Atogepant	Antimigraine Agent	10 mg, 30 mg, 60 mg	Tablet	N/A	Non-Formulary
7/1/22	Vuity	Pilocarpine	Anti-glaucoma Agent	1.25 %	Solution	N/A	PA Required QL: 5 mL/30 days
7/1/22	Bylvy	Odevixibat	Bile acid transporter inhibitor	200 mcg, 400 mcg, 600 mcg, 1200 mcg	Capsule, Capsule Sprinkle	N/A	Non-Formulary
7/1/22	Opzelura	Ruxolitinib	Atopic Dermatitis	1.5 %	Cream	N/A	Non-Formulary
7/1/22	Adbry	Tralokinumab	Atopic Dermatitis	150 mg/mL	Solution Prefilled Syringe	N/A	Non-Formulary
7/1/22	Livtency	Maribavir	Antiviral Agent	200mg	Tablet	N/A	PA Required QL: 112/28 days
7/1/22	Tarpeyo	Budesonide	Primary immunoglobulin A nephropathy	4 mg	Capsule Delayed Release	N/A	PA Required QL: 120/30 days
7/1/22	Besremi	Ropeginterferon alfa-2b-NJFT	Antineoplastic	500 mcg/mL	Solution Prefilled Syringe	PA Required	PA Required NSO
7/1/22	Pemfexy	Pemetrexed	Antineoplastic	25 mg/mL	Solution	PA Required	PA Required NSO
7/1/22	Kimmtrak	Tebentafusp-tebn	Antineoplastic	100 mg/0.5mL	Solution	PA Required	PA Required NSO

N/A=Not Applicable, NSO = New Starts Only, PA = Prior Authorization, QL = Quantity Limit